Difference between revisions of "Rivaroxaban (Xarelto)"
m |
m |
||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2011-07-01: Approved for the prophylaxis of [[Venous thromboembolism|DVT]], which may lead to PE in patients undergoing knee or hip replacement surgery. |
| − | *11 | + | *2011-11-04: Approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ''(Non-hematologic indication)'' |
| − | *11 | + | *2012-11-02: Approved for the treatment of [[Venous thromboembolism|deep vein thrombosis (DVT), pulmonary embolism (PE)]], and for the reduction in the risk of recurrence of DVT and of PE. |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2008-09-30: Initial authorization |
==Also known as== | ==Also known as== | ||
*'''Code name:''' BAY 59-7939 | *'''Code name:''' BAY 59-7939 | ||
Revision as of 13:14, 9 May 2023
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Reversal information
Factor Xa, recombinant, inactivated-zhzo (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
Diseases for which it is used
- Atrial fibrillation
- Venous thromboembolism
Patient drug information
- Rivaroxaban (Xarelto) package insert[1]
- Rivaroxaban (Xarelto) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2011-07-01: Approved for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
- 2011-11-04: Approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (Non-hematologic indication)
- 2012-11-02: Approved for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE.
History of changes in EMA indication
- 2008-09-30: Initial authorization
Also known as
- Code name: BAY 59-7939
- Brand name: Xarelto